Company overview
Oxford Gene Technology (OGT) is a leading global provider of diagnostic genomic solutions and biomarker discovery platforms for precision medicine. The company offers comprehensive NGS panels, cytogenetics arrays, FISH probes, and microarray services designed for cancer detection, inherited genetic disease identification, and clinical trial support. OGT serves pharmaceutical, diagnostic, and research organizations with FDA-cleared and IVDR-certified products across genomics, biomarkers, and licensing divisions.
Genomic Diagnostics & Biomarker Solutions is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services, Diagnostics & Testing partner serving United States & Americas. Core focus areas include genomic diagnostics, ngs panels, fish probes, biomarker discovery, companion diagnostics, cytogenetics.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.ogt.com
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- genomic diagnostics, ngs panels, fish probes, biomarker discovery, companion diagnostics, cytogenetics, precision medicine, clinical trial assays, cancer diagnostics
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are OGT's core product offerings for pharmaceutical R&D?
- OGT provides next-generation sequencing (NGS) panels with unparalleled coverage completeness, cytogenetics arrays (CytoSure range), FISH probes for gene rearrangement detection, microarray consultancy services, and tailored biomarker discovery solutions. Their portfolio includes FDA-cleared and IVDR-certified products specifically designed for hematological malignancies and cancer diagnostics.
- Does OGT support clinical trial and companion diagnostic development?
- Yes. OGT operates a dedicated Precision Medicine Partnering team that accelerates clinical trial assay and companion diagnostic (CDx) development programs. They offer existing comprehensive portfolios of hematological malignancy-focused NGS clinical research products and can support custom assay development.
- What regulatory certifications and geographic presence does OGT have?
- OGT's products carry FDA clearance and IVDR certification. The company maintains state-of-the-art facilities at its Oxford headquarters, a Cambridge office (following the Cytocell acquisition), and expanded NGS operations at Oxford Technology Park as of February 2024. OGT operates as a global provider with international reach.
- What is OGT's background and company structure?
- Founded by Professor Ed Southern and spun out of the University of Oxford in 1995, OGT operates three core commercial arms: Genomics, Biomarkers, and Licensing, plus an Exploratory Research division. The company has approximately 135 employees and has grown through strategic acquisitions including Sense Proteomic Ltd (2009) and Cytocell Limited (2014).
- What specialized capabilities does OGT offer for biomarker discovery?
- OGT develops tailored biomarker discovery solutions to identify novel markers for human diseases including cancer. Following the acquisition of Sense Proteomic Ltd, the company combines genomic and proteomic expertise to advance molecular medicine applications and support pharmaceutical partners in precision medicine development.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
